Differences in circulating insulin levels following glargine administration.
To evaluate two-site non competitive insulin immunoassays [BI-INSULIN assay (IRMA) and an electro-chemiluminescent immunoassay (ECLIA)] in routine practice. We studied 145 consecutive patients attending our Endocrine Department for general endocrine explorations and metabolic status investigations. The ECLIA yielded higher results than IRMA in all but six patients treated by glargine. Insulin levels measured by Elecsys in patients treated by glargine are directly related to glargine biotransformation into detectable metabolite (M1).